Executive Summary of the Vulvodynia Therapeutic Research Summit.
Krapf JM, Yong PJ, Berke MD, Bohm-Starke N, Bornstein J, Chrysilla E, Dempsey TT, Falsetta ML, Foster D, Goldstein SW, Iadarola MJ, Kellogg-Spadt S, Mannes AJ, Vogel J, Goldstein AT.
Krapf JM, et al.
Obstet Gynecol. 2026 Feb 1;147(2):266-276. doi: 10.1097/AOG.0000000000006118. Epub 2025 Nov 6.
Obstet Gynecol. 2026.
PMID: 41197126
The top identified therapeutics for further research were: 1) ketotifen fumarate (mast cell stabilizer with potential to prevent mast cell activation), 2) resiniferatoxin (transient receptor vanilloid 1 agonist causing chemo-inactivation of nerve terminals), 3) specialized pro-re …
The top identified therapeutics for further research were: 1) ketotifen fumarate (mast cell stabilizer with potential to prevent mast cell a …